{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:33:29Z","timestamp":1794652409526,"version":"4.9.1"},"reference-count":232,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1038\/s41584-023-00992-8","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T15:02:58Z","timestamp":1689174178000},"page":"560-575","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Effect of DMARDs on the immunogenicity of vaccines"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7382-8322","authenticated-orcid":false,"given":"Yannick","family":"van Sleen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2798-6765","authenticated-orcid":false,"given":"Kornelis S. M.","family":"van der Geest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke L. W.","family":"Huckriede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"van Baarle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5652-4423","authenticated-orcid":false,"given":"Elisabeth","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"key":"992_CR1","doi-asserted-by":"crossref","unstructured":"Holmes, K. K., Bertozzi, S., Bloom, B. R. & Jha, P. in Disease Control Priorities, (Volume 6): Major Infectious Diseases (World Bank Publications, 2017).","DOI":"10.1596\/978-1-4648-0524-0"},{"key":"992_CR2","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jhin.2020.05.021","volume":"105","author":"B Cookson","year":"2020","unstructured":"Cookson, B. Regarding \u201cUnderstanding the emerging coronavirus: what it means to health security and infection prevention\u201d. J. Hosp. Infect. 105, 792 (2020).","journal-title":"J. Hosp. Infect."},{"key":"992_CR3","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1126\/science.aap7463","volume":"359","author":"D Carroll","year":"2018","unstructured":"Carroll, D. et al. The global virome project. Science 359, 872\u2013874 (2018).","journal-title":"Science"},{"key":"992_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","volume":"21","author":"AJ Pollard","year":"2021","unstructured":"Pollard, A. J. & Bijker, E. M. A guide to vaccinology: from basic principles to new developments. Nat. Rev. Immunol. 21, 83\u2013100 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"992_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines \u2014 a new era in vaccinology. Nat. Rev. Drug. Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"992_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.anai.2021.08.413","volume":"127","author":"KS Tuano","year":"2021","unstructured":"Tuano, K. S., Seth, N. & Chinen, J. Secondary immunodeficiencies: an overview. Ann. Allergy Asthma Immunol. 127, 617\u2013626 (2021).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"992_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13223-018-0278-1","volume":"14","author":"JS Marshall","year":"2018","unstructured":"Marshall, J. S., Warrington, R., Watson, W. & Kim, H. L. An introduction to immunology and immunopathology. Allergy Asthma Clin. Immunol. 14, 1\u201310 (2018).","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"992_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1159\/000493390","volume":"27","author":"J Bullock","year":"2018","unstructured":"Bullock, J. et al. Rheumatoid arthritis: a brief overview of the treatment. Med. Princ. Pract. 27, 501\u2013507 (2018).","journal-title":"Med. Princ. Pract."},{"key":"992_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","volume":"42","author":"J Youssef","year":"2016","unstructured":"Youssef, J., Novosad, S. A. & Winthrop, K. L. Infection risk and safety of corticosteroid use. Rheum. Dis. Clin. 42, 157\u2013176 (2016).","journal-title":"Rheum. Dis. Clin."},{"key":"992_CR10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/annrheumdis-2021-221575","volume":"81","author":"FPB Kroon","year":"2022","unstructured":"Kroon, F. P. B. et al. Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. Ann. Rheum. Dis. 81, 422\u2013432 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/annrheumdis-2021-221461","volume":"81","author":"H Bower","year":"2022","unstructured":"Bower, H., Frisell, T., Di Giuseppe, D., Delcoigne, B. & Askling, J. Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19? Ann. Rheum. Dis. 81, 433\u2013439 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-021-06548-z","volume":"21","author":"J Li","year":"2021","unstructured":"Li, J. et al. Association between glucocorticoids treatment and viral clearance delay in patients with COVID-19: a systematic review and meta-analysis. BMC Infect. Dis. 21, 1\u201313 (2021).","journal-title":"BMC Infect. Dis."},{"key":"992_CR13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41577-021-00578-z","volume":"21","author":"M Sadarangani","year":"2021","unstructured":"Sadarangani, M., Marchant, A. & Kollmann, T. R. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat. Rev. Immunol. 21, 475\u2013484 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"992_CR14","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3389\/fimmu.2014.00630","volume":"5","author":"J Geginat","year":"2014","unstructured":"Geginat, J. et al. Plasticity of human CD4 T cell subsets. Front. Immunol. 5, 630 (2014).","journal-title":"Front. Immunol."},{"key":"992_CR15","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/nature06246","volume":"449","author":"R Medzhitov","year":"2007","unstructured":"Medzhitov, R. Recognition of microorganisms and activation of the immune response. Nature 449, 819\u2013826 (2007).","journal-title":"Nature"},{"key":"992_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0065-2776(10)05004-2","volume":"105","author":"K Fujio","year":"2010","unstructured":"Fujio, K., Okamura, T. & Yamamoto, K. The family of IL-10-secreting CD4+ T cells. Adv. Immunol. 105, 99\u2013130 (2010).","journal-title":"Adv. Immunol."},{"key":"992_CR17","doi-asserted-by":"publisher","first-page":"101495","DOI":"10.1016\/j.trim.2021.101495","volume":"70","author":"E Aleebrahim-Dehkordi","year":"2022","unstructured":"Aleebrahim-Dehkordi, E. et al. T helper type (Th1\/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: from cytokines produced to immune responses. Transpl. Immunol. 70, 101495 (2022).","journal-title":"Transpl. Immunol."},{"key":"992_CR18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-021-03841-4","volume":"597","author":"V Oberhardt","year":"2021","unstructured":"Oberhardt, V. et al. Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine. Nature 597, 268\u2013273 (2021).","journal-title":"Nature"},{"key":"992_CR19","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","volume":"185","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell 185, 2434\u20132451 (2022).","journal-title":"Cell"},{"key":"992_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","volume":"4","author":"F Krammer","year":"2018","unstructured":"Krammer, F. et al. Influenza. Nat. Rev. Dis. Prim. 4, 3 (2018).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"992_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","volume":"398","author":"MD Tanriover","year":"2021","unstructured":"Tanriover, M. D. et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 398, 213\u2013222 (2021).","journal-title":"Lancet"},{"key":"992_CR22","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","volume":"385","author":"PT Heath","year":"2021","unstructured":"Heath, P. T. et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N. Engl. J. Med. 385, 1172\u20131183 (2021).","journal-title":"N. Engl. J. Med."},{"key":"992_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-02321-z","volume":"11","author":"V Rotshild","year":"2021","unstructured":"Rotshild, V., Hirsh-Raccah, B., Miskin, I., Muszkat, M. & Matok, I. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci. Rep. 11, 1\u20139 (2021).","journal-title":"Sci. Rep."},{"key":"992_CR24","doi-asserted-by":"publisher","first-page":"789427","DOI":"10.3389\/fcell.2021.789427","volume":"9","author":"P Morais","year":"2021","unstructured":"Morais, P., Adachi, H. & Yu, Y. T. The critical contribution of pseudouridine to mRNA COVID-19 vaccines. Front. Cell. Dev. Biol. 9, 789427 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"key":"992_CR25","doi-asserted-by":"publisher","first-page":"646677","DOI":"10.3389\/fimmu.2021.646677","volume":"12","author":"P Zimmermann","year":"2021","unstructured":"Zimmermann, P. et al. Correlation of vaccine responses. Front. Immunol. 12, 646677 (2021).","journal-title":"Front. Immunol."},{"key":"992_CR26","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41586-021-04085-y","volume":"600","author":"C Lucas","year":"2021","unstructured":"Lucas, C. et al. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature 600, 523\u2013529 (2021).","journal-title":"Nature"},{"key":"992_CR27","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/S1470-2045(21)00574-X","volume":"22","author":"SF Oosting","year":"2021","unstructured":"Oosting, S. F. et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol. 22, 1681\u20131691 (2021).","journal-title":"Lancet Oncol."},{"key":"992_CR28","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1093\/infdis\/jiaa415","volume":"222","author":"J Schlom","year":"2020","unstructured":"Schlom, J. & Donahue, R. N. The importance of cellular immunity in the development of vaccines and therapeutics for COVID-19. J. Infect. Dis. 222, 1435\u20131438 (2020).","journal-title":"J. Infect. Dis."},{"key":"992_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1586\/erv.10.169","volume":"10","author":"M Slota","year":"2011","unstructured":"Slota, M., Lim, J., Dang, Y. & Disis, M. L. ELISpot for measuring human immune responses to vaccines. Expert Rev. Vaccines 10, 299\u2013306 (2011).","journal-title":"Expert Rev. Vaccines"},{"key":"992_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.15586\/aei.v50i3.583","volume":"50","author":"Y Barrios","year":"2022","unstructured":"Barrios, Y. et al. Easy approach to detect cell immunity to COVID vaccines in common variable immunodeficiency patients. Allergol. Immunopathol. 50, 101\u2013105 (2022).","journal-title":"Allergol. Immunopathol."},{"key":"992_CR31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/vaccines9020147","volume":"9","author":"E Bettini","year":"2021","unstructured":"Bettini, E. & Locci, M. SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond. Vaccines 9, 147 (2021).","journal-title":"Vaccines"},{"key":"992_CR32","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/art.33418","volume":"64","author":"M Rossol","year":"2012","unstructured":"Rossol, M., Kraus, S., Pierer, M., Baerwald, C. & Wagner, U. The CD14bright CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population. Arthritis Rheum. 64, 671\u2013677 (2012).","journal-title":"Arthritis Rheum."},{"key":"992_CR33","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1002\/art.34647","volume":"64","author":"M Samson","year":"2012","unstructured":"Samson, M. et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum. 64, 3788\u20133798 (2012).","journal-title":"Arthritis Rheum."},{"key":"992_CR34","doi-asserted-by":"publisher","first-page":"870","DOI":"10.7326\/M20-1594","volume":"173","author":"MD George","year":"2020","unstructured":"George, M. D. et al. Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: a cohort study. Ann. Intern. Med. 173, 870\u2013878 (2020).","journal-title":"Ann. Intern. Med."},{"key":"992_CR35","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/art.42030","volume":"74","author":"R Conway","year":"2022","unstructured":"Conway, R. et al. SARS\u2013CoV\u20102 infection and COVID\u201019 outcomes in rheumatic diseases: a systematic literature review and meta\u2010analysis. Arthritis Rheumatol. 74, 766\u2013775 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"992_CR36","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3899\/jrheum.170710","volume":"45","author":"S Subesinghe","year":"2018","unstructured":"Subesinghe, S., Bechman, K., Rutherford, A. I., Goldblatt, D. & Galloway, J. B. A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis. J. Rheumatol. 45, 733\u2013744 (2018).","journal-title":"J. Rheumatol."},{"key":"992_CR37","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1136\/annrheumdis-2021-221244","volume":"80","author":"MA Friedman","year":"2021","unstructured":"Friedman, M. A., Curtis, J. R. & Winthrop, K. L. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Ann. Rheum. Dis. 80, 1255\u20131265 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001035","volume":"5","author":"C Rondaan","year":"2019","unstructured":"Rondaan, C. et al. Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations. RMD Open 5, e001035 (2019).","journal-title":"RMD Open"},{"key":"992_CR39","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/art.30325","volume":"63","author":"C Gabay","year":"2011","unstructured":"Gabay, C. et al. Impact of synthetic and biologic disease\u2010modifying antirheumatic drugs on antibody responses to the AS03\u2010adjuvanted pandemic influenza vaccine: a prospective, open\u2010label, parallel\u2010cohort, single\u2010center study. Arthritis Rheum. 63, 1486\u20131496 (2011).","journal-title":"Arthritis Rheum."},{"key":"992_CR40","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/art.25033","volume":"62","author":"S Van Assen","year":"2010","unstructured":"Van Assen, S. et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 62, 75\u201381 (2010).","journal-title":"Arthritis Rheum."},{"key":"992_CR41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer, V. et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann. Rheum. Dis. 79, 39\u201352 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR42","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/acr.25045","volume":"75","author":"AR Bass","year":"2023","unstructured":"Bass, A. R. et al. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Care Res. 75, 449\u2013464 (2023).","journal-title":"Arthritis Care Res."},{"key":"992_CR43","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.vaccine.2010.12.072","volume":"29","author":"U Arad","year":"2011","unstructured":"Arad, U. et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 29, 1643\u20131648 (2011).","journal-title":"Vaccine"},{"key":"992_CR44","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1136\/annrheumdis-2021-220435","volume":"80","author":"T Graalmann","year":"2021","unstructured":"Graalmann, T. et al. B cell depletion impairs vaccination-induced CD8+ T cell responses in a type I interferon-dependent manner. Ann. Rheum. Dis. 80, 1537\u20131544 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR45","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/rheumatology\/ker389","volume":"51","author":"S Adler","year":"2012","unstructured":"Adler, S. et al. Protective effect of A\/H1N1 vaccination in immune-mediated disease \u2014 a prospectively controlled vaccination study. Rheumatology 51, 695\u2013700 (2012).","journal-title":"Rheumatology"},{"key":"992_CR46","first-page":"2555","volume":"29","author":"M Abu-Shakra","year":"2002","unstructured":"Abu-Shakra, M. et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J. Rheumatol. 29, 2555\u20132557 (2002).","journal-title":"J. Rheumatol."},{"key":"992_CR47","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1002\/art.24679","volume":"60","author":"A Holvast","year":"2009","unstructured":"Holvast, A. et al. Studies of cell\u2010mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis Rheum. 60, 2438\u20132447 (2009).","journal-title":"Arthritis Rheum."},{"key":"992_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12891-016-1082-z","volume":"17","author":"R Alten","year":"2016","unstructured":"Alten, R. et al. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. BMC Musculoskelet. Disord. 17, 1\u201310 (2016).","journal-title":"BMC Musculoskelet. Disord."},{"key":"992_CR49","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/acr.21838","volume":"65","author":"AC Ribeiro","year":"2013","unstructured":"Ribeiro, A. C. et al. Abatacept and reduced immune response to pandemic 2009 influenza A\/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res. 65, 476\u2013480 (2013).","journal-title":"Arthritis Care Res."},{"key":"992_CR50","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/acr.21948","volume":"65","author":"LM Campos","year":"2013","unstructured":"Campos, L. M. et al. High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus. Arthritis Care Res. 65, 1121\u20131127 (2013).","journal-title":"Arthritis Care Res."},{"key":"992_CR51","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003637","volume":"95","author":"Y Huang","year":"2016","unstructured":"Huang, Y., Wang, H., Wan, L., Lu, X. & Tam, W. W. S. Is systemic lupus erythematosus associated with a declined immunogenicity and poor safety of influenza vaccination?: a systematic review and meta-analysis. Medicine 95, e3637 (2016).","journal-title":"Medicine"},{"key":"992_CR52","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1080\/03007995.2017.1329140","volume":"33","author":"Y Huang","year":"2017","unstructured":"Huang, Y., Wang, H. & Tam, W. W. Is rheumatoid arthritis associated with reduced immunogenicity of the influenza vaccination? A systematic review and meta-analysis. Curr. Med. Res. Opin. 33, 1901\u20131908 (2017).","journal-title":"Curr. Med. Res. Opin."},{"key":"992_CR53","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1136\/ard.2011.152983","volume":"70","author":"AC Ribeiro","year":"2011","unstructured":"Ribeiro, A. C. et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann. Rheum. Dis. 70, 2144\u20132147 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR54","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/acr.22246","volume":"66","author":"C Hua","year":"2014","unstructured":"Hua, C., Barnetche, T., Combe, B. & Morel, J. Effect of methotrexate, anti\u2013tumor necrosis factor \u03b1, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta\u2010analysis. Arthritis Care Res. 66, 1016\u20131026 (2014).","journal-title":"Arthritis Care Res."},{"key":"992_CR55","first-page":"898","volume":"77","author":"JK Park","year":"2018","unstructured":"Park, J. K. et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann. Rheum. Dis. 77, 898\u2013904 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR56","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1136\/annrheumdis-2017-211128","volume":"76","author":"JK Park","year":"2017","unstructured":"Park, J. K. et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann. Rheum. Dis. 76, 1559\u20131565 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR57","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/rheumatology\/kel366","volume":"46","author":"MC Kapetanovic","year":"2007","unstructured":"Kapetanovic, M. C., Saxne, T., Nilsson, J. & Geborek, P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology 46, 608\u2013611 (2007).","journal-title":"Rheumatology"},{"key":"992_CR58","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1136\/annrheumdis-2014-207191","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop, K. L. et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann. Rheum. Dis. 75, 687\u2013695 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR59","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1093\/rheumatology\/ker427","volume":"51","author":"EF Borba","year":"2012","unstructured":"Borba, E. F. et al. Influenza A\/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy? Rheumatology 51, 1061\u20131069 (2012).","journal-title":"Rheumatology"},{"key":"992_CR60","doi-asserted-by":"publisher","first-page":"102927","DOI":"10.1016\/j.autrev.2021.102927","volume":"21","author":"A Jena","year":"2022","unstructured":"Jena, A. et al. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis. Autoimmun. Rev. 21, 102927 (2022).","journal-title":"Autoimmun. Rev."},{"key":"992_CR61","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/annrheumdis-2021-222096","volume":"81","author":"NE Aikawa","year":"2022","unstructured":"Aikawa, N. E. et al. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. Ann. Rheum. Dis. 81, 1036\u20131043 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR62","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.7326\/M21-1757","volume":"174","author":"P Deepak","year":"2021","unstructured":"Deepak, P. et al. Glucocorticoids and B cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2. Ann. Intern. Med., 174, 1572\u20131585 (2021).","journal-title":"Ann. Intern. Med."},{"key":"992_CR63","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002036","volume":"8","author":"S Schietzel","year":"2022","unstructured":"Schietzel, S. et al. Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients. RMD Open 8, e002036 (2022).","journal-title":"RMD Open"},{"key":"992_CR64","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41591-021-01507-2","volume":"27","author":"SA Apostolidis","year":"2021","unstructured":"Apostolidis, S. A. et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nat. Med. 27, 1990\u20132001 (2021).","journal-title":"Nat. Med."},{"key":"992_CR65","doi-asserted-by":"publisher","first-page":"e778","DOI":"10.1016\/S2665-9913(21)00222-8","volume":"3","author":"L Boekel","year":"2021","unstructured":"Boekel, L. et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatol. 3, e778\u2013e788 (2021).","journal-title":"Lancet Rheumatol."},{"key":"992_CR66","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1016\/S2665-9913(22)00034-0","volume":"4","author":"L Wieske","year":"2022","unstructured":"Wieske, L. et al. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. Lancet Rheumatol. 4, e338\u2013e350 (2022).","journal-title":"Lancet Rheumatol."},{"key":"992_CR67","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1136\/annrheumdis-2021-220503","volume":"80","author":"Y Braun-Moscovici","year":"2021","unstructured":"Braun-Moscovici, Y. et al. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann. Rheum. Dis. 80, 1317\u20131321 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR68","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3390\/vaccines10060901","volume":"10","author":"V Furer","year":"2022","unstructured":"Furer, V. et al. Predictors of immunogenic response to the BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases treated with rituximab. Vaccines 10, 901 (2022).","journal-title":"Vaccines"},{"key":"992_CR69","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1136\/annrheumdis-2021-221554","volume":"81","author":"D Simon","year":"2022","unstructured":"Simon, D. et al. Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease. Ann. Rheum. Dis. 81, 1023\u20131027 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR70","doi-asserted-by":"publisher","first-page":"e1037","DOI":"10.1093\/cid\/ciab954","volume":"75","author":"N Madelon","year":"2022","unstructured":"Madelon, N. et al. Robust T-cell responses in anti-CD20-treated patients following COVID-19 vaccination: a prospective cohort study. Clin. Infect. Dis. 75, e1037\u2013e1045 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"992_CR71","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S2468-1253(22)00274-6","volume":"7","author":"JL Alexander","year":"2022","unstructured":"Alexander, J. L. et al. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study. Lancet Gastroenterol. Hepatol. 7, 1005\u20131015 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"992_CR72","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1007\/s10067-022-06329-2","volume":"41","author":"A Sch\u00e4fer","year":"2022","unstructured":"Sch\u00e4fer, A., Kovacs, M. S., Eder, A., Nigg, A. & Feuchtenberger, M. Janus kinase (JAK) inhibitors significantly reduce the humoral vaccination response against SARS-CoV-2 in patients with rheumatoid arthritis. Clin. Rheumatol. 41, 3707\u20133714 (2022).","journal-title":"Clin. Rheumatol."},{"key":"992_CR73","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.7326\/M21-1757","volume":"174","author":"P Deepak","year":"2021","unstructured":"Deepak, P. et al. Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study. Ann. Intern. Med. 174, 1572\u20131585 (2021).","journal-title":"Ann. Intern. Med."},{"key":"992_CR74","doi-asserted-by":"publisher","first-page":"901055","DOI":"10.3389\/fimmu.2022.901055","volume":"13","author":"D Mauro","year":"2022","unstructured":"Mauro, D. et al. Serological response to BNT162b2 anti-SARS-CoV-2 vaccination in patients with inflammatory rheumatic diseases: results from the RHEUVAX cohort. Front. Immunol. 13, 901055 (2022).","journal-title":"Front. Immunol."},{"key":"992_CR75","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","volume":"80","author":"V Furer","year":"2021","unstructured":"Furer, V. et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Ann. Rheum. Dis. 80, 1330\u20131338 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR76","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1002\/art.42153","volume":"74","author":"SW Syversen","year":"2022","unstructured":"Syversen, S. W. et al. Immunogenicity and safety of standard and third\u2010dose SARS-CoV\u20102 vaccination in patients receiving immunosuppressive therapy. Arthritis Rheumatol. 74, 1321\u20131332 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"992_CR77","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001898","author":"C Sieiro Santos","year":"2022","unstructured":"Sieiro Santos, C. et al. Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases. RMD Open https:\/\/doi.org\/10.1136\/rmdopen-2021-001898 (2022).","journal-title":"RMD Open"},{"key":"992_CR78","doi-asserted-by":"publisher","first-page":"462","DOI":"10.14309\/ajg.0000000000001619","volume":"117","author":"MD Kappelman","year":"2022","unstructured":"Kappelman, M. D. et al. Factors affecting initial humoral immune response to SARS-CoV-2 vaccines among patients with inflammatory bowel diseases. Am. J. Gastroenterol. 117, 462\u2013469 (2022).","journal-title":"Am. J. Gastroenterol."},{"key":"992_CR79","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1136\/annrheumdis-2021-220626","volume":"80","author":"M Prendecki","year":"2021","unstructured":"Prendecki, M. et al. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Ann. Rheum. Dis. 80, 1322\u20131329 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR80","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/mr\/roac030","volume":"33","author":"Y Kashiwado","year":"2022","unstructured":"Kashiwado, Y. et al. Antibody response to SARS-CoV-2 mRNA vaccines in patients with rheumatic diseases in Japan: interim analysis of a multicenter cohort study. Mod. Rheumatol. 33, 367\u2013372 (2022).","journal-title":"Mod. Rheumatol."},{"key":"992_CR81","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000031288","volume":"101","author":"K Sugihara","year":"2022","unstructured":"Sugihara, K. et al. Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: a Japanese monocentric study. Medicine 101, e31288 (2022).","journal-title":"Medicine"},{"key":"992_CR82","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002479","volume":"8","author":"Y van Sleen","year":"2022","unstructured":"van Sleen, Y. et al. Humoral and cellular SARS-CoV-2 vaccine responses in patients with giant cell arteritis and polymyalgia rheumatica. RMD Open 8, e002479 (2022).","journal-title":"RMD Open"},{"key":"992_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-18996-x","volume":"12","author":"S Garcia-Cirera","year":"2022","unstructured":"Garcia-Cirera, S. et al. Glucocorticoids\u2019 treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in systemic lupus erythematosus patients. Sci. Rep. 12, 1\u20139 (2022).","journal-title":"Sci. Rep."},{"key":"992_CR84","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1038\/s41591-021-01469-5","volume":"27","author":"AC Medeiros-Ribeiro","year":"2021","unstructured":"Medeiros-Ribeiro, A. C. et al. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat. Med. 27, 1744\u20131751 (2021).","journal-title":"Nat. Med."},{"key":"992_CR85","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/art.41937","volume":"74","author":"PM Izmirly","year":"2022","unstructured":"Izmirly, P. M. et al. Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS-CoV\u20102 vaccination. Arthritis Rheumatol. 74, 284\u2013294 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"992_CR86","doi-asserted-by":"publisher","first-page":"SI180","DOI":"10.1093\/rheumatology\/keac089","volume":"61","author":"M Krasselt","year":"2022","unstructured":"Krasselt, M. et al. Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions. Rheumatology 61, SI180\u2013SI188 (2022).","journal-title":"Rheumatology"},{"key":"992_CR87","doi-asserted-by":"publisher","first-page":"1759720X2210895","DOI":"10.1177\/1759720X221089586","volume":"14","author":"H So","year":"2022","unstructured":"So, H., Li, T., Chan, V., Tam, L. & Chan, P. K. Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus. Ther. Adv. Musculoskelet. Dis. 14, 1759720X221089586 (2022).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"992_CR88","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/rheumatology\/keab776","volume":"61","author":"P Delvino","year":"2022","unstructured":"Delvino, P. et al. Impact of immunosuppressive treatment on the immunogenicity of mRNA Covid-19 vaccine in vulnerable patients with giant cell arteritis. Rheumatology 61, 870\u2013872 (2022).","journal-title":"Rheumatology"},{"key":"992_CR89","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/annrheumdis-2021-221735","volume":"81","author":"AC Medeiros-Ribeiro","year":"2022","unstructured":"Medeiros-Ribeiro, A. C. et al. Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis. Ann. Rheum. Dis. 81, 710\u2013719 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR90","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1093\/rheumatology\/keac365","volume":"62","author":"S Monti","year":"2023","unstructured":"Monti, S. et al. Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis. Rheumatology 62, 726\u2013734 (2023).","journal-title":"Rheumatology"},{"key":"992_CR91","doi-asserted-by":"publisher","first-page":"e627","DOI":"10.1016\/S2665-9913(21)00212-5","volume":"3","author":"SK Mahil","year":"2021","unstructured":"Mahil, S. K. et al. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. Lancet Rheumatol. 3, e627\u2013e637 (2021).","journal-title":"Lancet Rheumatol."},{"key":"992_CR92","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","volume":"80","author":"RH Haberman","year":"2021","unstructured":"Haberman, R. H. et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease. Ann. Rheum. Dis. 80, 1339\u20131344 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR93","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1136\/annrheumdis-2021-221876","volume":"81","author":"AN Arumahandi De Silva","year":"2022","unstructured":"Arumahandi De Silva, A. N. et al. Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases. Ann. Rheum. Dis. 81, 881\u2013888 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR94","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002639","author":"E Habermann","year":"2022","unstructured":"Habermann, E. et al. Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination. RMD Open https:\/\/doi.org\/10.1136\/rmdopen-2022-002639 (2022).","journal-title":"RMD Open"},{"key":"992_CR95","doi-asserted-by":"publisher","first-page":"e755","DOI":"10.1016\/S2665-9913(22)00228-4","volume":"4","author":"TG Skaria","year":"2022","unstructured":"Skaria, T. G. et al. Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials. Lancet Rheumatol. 4, e755\u2013e764 (2022).","journal-title":"Lancet Rheumatol."},{"key":"992_CR96","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1136\/annrheumdis-2021-221916","volume":"81","author":"CSR Araujo","year":"2022","unstructured":"Araujo, C. S. R. et al. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial. Ann. Rheum. Dis. 81, 889\u2013897 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR97","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159721","volume":"7","author":"RM Dayam","year":"2022","unstructured":"Dayam, R. M. et al. Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune mediated inflammatory diseases. JCI Insight 7, e159721 (2022).","journal-title":"JCI Insight"},{"key":"992_CR98","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1053\/j.gastro.2021.10.029","volume":"162","author":"H Edelman-Klapper","year":"2022","unstructured":"Edelman-Klapper, H. et al. Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with Anti-TNF\u03b1. Gastroenterology 162, 454\u2013467 (2022).","journal-title":"Gastroenterology"},{"key":"992_CR99","doi-asserted-by":"publisher","first-page":"105464","DOI":"10.1016\/j.jbspin.2022.105464","volume":"90","author":"CG Saad","year":"2023","unstructured":"Saad, C. G. et al. Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis. Jt. Bone Spine 90, 105464 (2023).","journal-title":"Jt. Bone Spine"},{"key":"992_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28517-z","volume":"13","author":"S Lin","year":"2022","unstructured":"Lin, S. et al. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nat. Commun. 13, 1379 (2022).","journal-title":"Nat. Commun."},{"key":"992_CR101","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1002\/jmv.28063","volume":"94","author":"UM Geisen","year":"2022","unstructured":"Geisen, U. M. et al. The long term vaccine\u2010induced anti\u2010SARS\u2010CoV\u20102 immune response is impaired in quantity and quality under TNF\u03b1 blockade. J. Med. Virol. 94, 5780\u20135789 (2022).","journal-title":"J. Med. Virol."},{"key":"992_CR102","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3390\/jpm12050694","volume":"12","author":"R Vollenberg","year":"2022","unstructured":"Vollenberg, R., Tepasse, P., Lorentzen, E. & Nowacki, T. M. Impaired humoral immunity with concomitant preserved T cell reactivity in IBD patients on treatment with infliximab 6 month after vaccination with the SARS-CoV-2 mRNA vaccine BNT162b2: a pilot study. J. Pers. Med. 12, 694 (2022).","journal-title":"J. Pers. Med."},{"key":"992_CR103","doi-asserted-by":"publisher","first-page":"1033804","DOI":"10.3389\/fimmu.2022.1033804","volume":"13","author":"J Wro\u0144ski","year":"2022","unstructured":"Wro\u0144ski, J. et al. Humoral and cellular immunogenicity of COVID-19 booster dose vaccination in inflammatory arthritis patients. Front. Immunol. 13, 1033804 (2022).","journal-title":"Front. Immunol."},{"key":"992_CR104","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/acr.24824","volume":"74","author":"EF Yuki","year":"2022","unstructured":"Yuki, E. F. et al. Impact of distinct therapies on antibody response to SARS\u2010CoV\u20102 vaccine in systemic lupus erythematosus. Arthritis Care Res. 74, 562\u2013571 (2022).","journal-title":"Arthritis Care Res."},{"key":"992_CR105","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002265","volume":"8","author":"GM Verstappen","year":"2022","unstructured":"Verstappen, G. M. et al. Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjogren\u2019s syndrome. RMD Open 8, e002265 (2022).","journal-title":"RMD Open"},{"key":"992_CR106","doi-asserted-by":"publisher","first-page":"978272","DOI":"10.3389\/fmed.2022.978272","volume":"9","author":"T Zhao","year":"2022","unstructured":"Zhao, T. et al. Third dose of anti-SARS-CoV-2 inactivated vaccine for patients with RA: focusing on immunogenicity and effects of RA drugs. Front. Med. 9, 978272 (2022).","journal-title":"Front. Med."},{"key":"992_CR107","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002632","volume":"8","author":"D Stahl","year":"2022","unstructured":"Stahl, D. et al. Reduced humoral response to a third dose (booster) of SARS-CoV-2 mRNA vaccines by concomitant methotrexate therapy in elderly patients with rheumatoid arthritis. RMD Open 8, e002632 (2022).","journal-title":"RMD Open"},{"key":"992_CR108","doi-asserted-by":"publisher","first-page":"102996","DOI":"10.1016\/j.jaut.2023.102996","volume":"135","author":"A Ten Hagen","year":"2023","unstructured":"Ten Hagen, A. et al. Improvement of humoral immunity by repeated dose-intensified COVID-19 vaccinations in primary non-to low-responders and B cell deficient rheumatic disease patients. J. Autoimmun. 135, 102996 (2023).","journal-title":"J. Autoimmun."},{"key":"992_CR109","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1136\/ard-2022-222579","volume":"81","author":"D Mrak","year":"2022","unstructured":"Mrak, D. et al. Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study. Ann. Rheum. Dis. 81, 1750\u20131756 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR110","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1136\/ard-2022-222550","volume":"81","author":"V Furer","year":"2022","unstructured":"Furer, V. et al. Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study. Ann. Rheum. Dis. 81, 1594\u20131602 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR111","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S2213-2600(22)00186-2","volume":"10","author":"A Abhishek","year":"2022","unstructured":"Abhishek, A. et al. Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial. Lancet Respir. Med. 10, 840\u2013850 (2022).","journal-title":"Lancet Respir. Med."},{"key":"992_CR112","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fmed.2023.1049157","volume":"10","author":"S Tobudic","year":"2023","unstructured":"Tobudic, S. et al. Accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccination. Front. Med. 10, 68 (2023).","journal-title":"Front. Med."},{"key":"992_CR113","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002871","volume":"9","author":"AP Tran","year":"2023","unstructured":"Tran, A. P., Tassone, D., Ding, N. & Nossent, J. Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2). RMD Open 9, e002871 (2023).","journal-title":"RMD Open"},{"key":"992_CR114","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/S2665-9913(21)00327-1","volume":"4","author":"NE Aikawa","year":"2022","unstructured":"Aikawa, N. E. et al. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. Lancet Rheumatol. 4, e113\u2013e124 (2022).","journal-title":"Lancet Rheumatol."},{"key":"992_CR115","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3390\/v13060965","volume":"13","author":"JJ Guthmiller","year":"2021","unstructured":"Guthmiller, J. J., Utset, H. A. & Wilson, P. C. B cell responses against influenza viruses: short-lived humoral immunity against a life-long threat. Viruses 13, 965 (2021).","journal-title":"Viruses"},{"key":"992_CR116","doi-asserted-by":"crossref","first-page":"6553-017","DOI":"10.1038\/s41598-017-06826-4","volume":"7","author":"Y van Sleen","year":"2017","unstructured":"van Sleen, Y. et al. Involvement of monocyte subsets in the immunopathology of giant cell arteritis. Sci. Rep. 7, 6553-017\u201306826-4 (2017).","journal-title":"Sci. Rep."},{"key":"992_CR117","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.3389\/fimmu.2019.01981","volume":"10","author":"Y van Sleen","year":"2019","unstructured":"van Sleen, Y. et al. Leukocyte dynamics reveal a persistent myeloid dominance in giant cell arteritis and polymyalgia rheumatica. Front. Immunol. 10, 1981 (2019).","journal-title":"Front. Immunol."},{"key":"992_CR118","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1189\/jlb.1202612","volume":"74","author":"F Dayyani","year":"2003","unstructured":"Dayyani, F. et al. Mechanism of glucocorticoid-induced depletion of human CD14+CD16+ monocytes. J. Leukoc. Biol. 74, 33\u201339 (2003).","journal-title":"J. Leukoc. Biol."},{"key":"992_CR119","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.clim.2006.04.567","volume":"120","author":"D Rozkova","year":"2006","unstructured":"Rozkova, D., Horvath, R., Bartunkova, J. & Spisek, R. Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. Clin. Immunol. 120, 260\u2013271 (2006).","journal-title":"Clin. Immunol."},{"key":"992_CR120","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","volume":"16","author":"BN Cronstein","year":"2020","unstructured":"Cronstein, B. N. & Aune, T. M. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat. Rev. Rheumatol. 16, 145\u2013154 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"992_CR121","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00011-005-1355-8","volume":"54","author":"S Herman","year":"2005","unstructured":"Herman, S., Zurgil, N. & Deutsch, M. Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm. Res. 54, 273\u2013280 (2005).","journal-title":"Inflamm. Res."},{"key":"992_CR122","first-page":"2551","volume":"27","author":"M Cutolo","year":"2000","unstructured":"Cutolo, M. et al. Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from patients with rheumatoid arthritis. J. Rheumatol. 27, 2551\u20132557 (2000).","journal-title":"J. Rheumatol."},{"key":"992_CR123","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/art.20764","volume":"52","author":"AI Catrina","year":"2005","unstructured":"Catrina, A. I. et al. Evidence that anti\u2013tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints. Arthritis Rheum. 52, 61\u201372 (2005).","journal-title":"Arthritis Rheum."},{"key":"992_CR124","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.clim.2005.01.007","volume":"115","author":"C Shen","year":"2005","unstructured":"Shen, C. et al. Infliximab induces apoptosis of monocytes and T lymphocytes in a human\u2013mouse chimeric model. Clin. Immunol. 115, 250\u2013259 (2005).","journal-title":"Clin. Immunol."},{"key":"992_CR125","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1136\/ard.2009.110502","volume":"69","author":"HM Baldwin","year":"2010","unstructured":"Baldwin, H. M., Ito-Ihara, T., Isaacs, J. D. & Hilkens, C. M. U. Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis. Ann. Rheum. Dis. 69, 1200\u20131207 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR126","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1165\/ajrcmb.19.4.2870","volume":"19","author":"JJ Brokaw","year":"1998","unstructured":"Brokaw, J. J. et al. Glucocorticoid-induced apoptosis of dendritic cells in the rat tracheal mucosa. Am. J. Respir. Cell Mol. Biol. 19, 598\u2013605 (1998).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"992_CR127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00594-1","volume":"11","author":"L Tamariz-Amador","year":"2021","unstructured":"Tamariz-Amador, L. et al. Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies. Blood Cancer J. 11, 1\u201313 (2021).","journal-title":"Blood Cancer J."},{"key":"992_CR128","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1016\/j.vaccine.2011.02.092","volume":"29","author":"D Anthony","year":"2011","unstructured":"Anthony, D. et al. Lower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individuals. Vaccine 29, 3558\u20133563 (2011).","journal-title":"Vaccine"},{"key":"992_CR129","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.3390\/v13112302","volume":"13","author":"MEH Kayesh","year":"2021","unstructured":"Kayesh, M. E. H., Kohara, M. & Tsukiyama-Kohara, K. An overview of recent insights into the response of tlr to SARS-CoV-2 infection and the potential of tlr agonists as SARS-CoV-2 vaccine adjuvants. Viruses 13, 2302 (2021).","journal-title":"Viruses"},{"key":"992_CR130","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","volume":"26","author":"S Linares-Fern\u00e1ndez","year":"2020","unstructured":"Linares-Fern\u00e1ndez, S., Lacroix, C., Exposito, J. & Verrier, B. Tailoring mRNA vaccine to balance innate\/adaptive immune response. Trends Mol. Med. 26, 311\u2013323 (2020).","journal-title":"Trends Mol. Med."},{"key":"992_CR131","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1146\/annurev.immunol.18.1.767","volume":"18","author":"J Banchereau","year":"2000","unstructured":"Banchereau, J. et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18, 767\u2013811 (2000).","journal-title":"Annu. Rev. Immunol."},{"key":"992_CR132","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.4049\/jimmunol.0901022","volume":"184","author":"A Panda","year":"2010","unstructured":"Panda, A. et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J. Immunol. 184, 2518\u20132527 (2010).","journal-title":"J. Immunol."},{"key":"992_CR133","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/exd.14059","volume":"29","author":"R Stalder","year":"2020","unstructured":"Stalder, R., Zhang, B., Jean Wrobel, L., Boehncke, W. & Brembilla, N. C. The Janus kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development. Exp. Dermatol. 29, 71\u201378 (2020).","journal-title":"Exp. Dermatol."},{"key":"992_CR134","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2005.06.029","volume":"122","author":"S Ogawa","year":"2005","unstructured":"Ogawa, S. et al. Molecular determinants of crosstalk between nuclear receptors and Toll-like receptors. Cell 122, 707\u2013721 (2005).","journal-title":"Cell"},{"key":"992_CR135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar2746","volume":"11","author":"C Richez","year":"2009","unstructured":"Richez, C. et al. Myeloid dendritic cells correlate with clinical response whereas plasmacytoid dendritic cells impact autoantibody development in rheumatoid arthritis patients treated with infliximab. Arthritis Res. Ther. 11, 1\u201310 (2009).","journal-title":"Arthritis Res. Ther."},{"key":"992_CR136","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/art.33411","volume":"64","author":"M Baldini","year":"2012","unstructured":"Baldini, M. et al. Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia. Arthritis Rheum. 64, 854\u2013865 (2012).","journal-title":"Arthritis Rheum."},{"key":"992_CR137","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1093\/rheumatology\/keh583","volume":"44","author":"S Wijngaarden","year":"2005","unstructured":"Wijngaarden, S., van Roon, J., van de Winkel, J., Bijlsma, J. & Lafeber, F. Down-regulation of activating Fc\u03b3 receptors on monocytes of patients with rheumatoid arthritis upon methotrexate treatment. Rheumatology 44, 729\u2013734 (2005).","journal-title":"Rheumatology"},{"key":"992_CR138","first-page":"1192","volume":"122","author":"A Heine","year":"2013","unstructured":"Heine, A. et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. J. Am. Soc. Hematol. 122, 1192\u20131202 (2013).","journal-title":"J. Am. Soc. Hematol."},{"key":"992_CR139","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1136\/ard.2006.054056","volume":"66","author":"T Ellingsen","year":"2007","unstructured":"Ellingsen, T., Hornung, N., Moller, B. K., Poulsen, J. H. & Stengaard-Pedersen, K. Differential effect of methotrexate on the increased CCR2 density on circulating CD4 T lymphocytes and monocytes in active chronic rheumatoid arthritis, with a down regulation only on monocytes in responders. Ann. Rheum. Dis. 66, 151\u2013157 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR140","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.imbio.2019.05.011","volume":"224","author":"C Falc\u00f3n-Beas","year":"2019","unstructured":"Falc\u00f3n-Beas, C. et al. Dexamethasone turns tumor antigen-presenting cells into tolerogenic dendritic cells with T cell inhibitory functions. Immunobiology 224, 697\u2013705 (2019).","journal-title":"Immunobiology"},{"key":"992_CR141","doi-asserted-by":"publisher","first-page":"690470","DOI":"10.3389\/fimmu.2021.690470","volume":"12","author":"BD Aevermann","year":"2021","unstructured":"Aevermann, B. D. et al. Machine learning-based single cell and integrative analysis reveals that baseline mDC predisposition correlates with hepatitis B vaccine antibody response. Front. Immunol. 12, 690470 (2021).","journal-title":"Front. Immunol."},{"key":"992_CR142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms7062","volume":"6","author":"M Miyata","year":"2015","unstructured":"Miyata, M. et al. Glucocorticoids suppress inflammation via the upregulation of negative regulator IRAK-M. Nat. Commun. 6, 1\u201312 (2015).","journal-title":"Nat. Commun."},{"key":"992_CR143","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1002\/1529-0131(199811)41:11<2032::AID-ART19>3.0.CO;2-J","volume":"41","author":"M Seitz","year":"1998","unstructured":"Seitz, M., Zwicker, M. & Loetscher, P. Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes. Arthritis Rheum. 41, 2032\u20132038 (1998).","journal-title":"Arthritis Rheum."},{"key":"992_CR144","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.jaci.2013.05.036","volume":"132","author":"PM Brunner","year":"2013","unstructured":"Brunner, P. M. et al. Infliximab induces downregulation of the IL-12\/IL-23 axis in 6-sulfo-LacNac (slan)+ dendritic cells and macrophages. J. Allergy Clin. Immunol. 132, 1184\u20131193 (2013).","journal-title":"J. Allergy Clin. Immunol."},{"key":"992_CR145","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1084\/jem.177.3.691","volume":"177","author":"A Celada","year":"1993","unstructured":"Celada, A., McKercher, S. & Maki, R. A. Repression of major histocompatibility complex IA expression by glucocorticoids: the glucocorticoid receptor inhibits the DNA binding of the X box DNA binding protein. J. Exp. Med. 177, 691\u2013698 (1993).","journal-title":"J. Exp. Med."},{"key":"992_CR146","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1097\/00007890-199610270-00016","volume":"62","author":"BJ Fessler","year":"1996","unstructured":"Fessler, B. J., Paliogianni, F., Hama, N., Balow, J. E. & Boumpas, D. T. Glucocorticoids modulate CD28 mediated pathways for interleukin 2 production in human T cells: evidence for posttranscriptional regulation. Transplantation 62, 1113\u20131118 (1996).","journal-title":"Transplantation"},{"key":"992_CR147","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/00007890-199808150-00015","volume":"66","author":"M Girndt","year":"1998","unstructured":"Girndt, M., Sester, U., Kaul, H., H\u00fcnger, F. & K\u00f6hler, H. Glucocorticoids inhibit activation-dependent expression of costimulatory molecule b7-1 in human monocytes. Transplantation 66, 370\u2013375 (1998).","journal-title":"Transplantation"},{"key":"992_CR148","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/cei.12870","volume":"187","author":"AE Anderson","year":"2017","unstructured":"Anderson, A. E. et al. Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4+ T cells partly via transforming growth factor-\u03b21. Clin. Exp. Immunol. 187, 113\u2013123 (2017).","journal-title":"Clin. Exp. Immunol."},{"key":"992_CR149","doi-asserted-by":"publisher","first-page":"i70","DOI":"10.1136\/annrheumdis-2011-200595","volume":"71","author":"Y Tanaka","year":"2012","unstructured":"Tanaka, Y., Maeshima, K. & Yamaoka, K. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis. Ann. Rheum. Dis. 71, i70\u2013i74 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-43899-9","volume":"9","author":"SC Furiati","year":"2019","unstructured":"Furiati, S. C. et al. Th1, Th17, and Treg responses are differently modulated by TNF-\u03b1 inhibitors and methotrexate in psoriasis patients. Sci. Rep. 9, 1\u201311 (2019).","journal-title":"Sci. Rep."},{"key":"992_CR151","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-88491-2","volume":"11","author":"P Nived","year":"2021","unstructured":"Nived, P. et al. Methotrexate reduces circulating Th17 cells and impairs plasmablast and memory B cell expansions following pneumococcal conjugate immunization in RA patients. Sci. Rep. 11, 1\u20139 (2021).","journal-title":"Sci. Rep."},{"key":"992_CR152","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/ced.13795","volume":"44","author":"M Priyadarssini","year":"2019","unstructured":"Priyadarssini, M., Chandrashekar, L. & Rajappa, M. Effect of methotrexate monotherapy on T\u2010cell subsets in the peripheral circulation in psoriasis. Clin. Exp. Dermatol. 44, 491\u2013497 (2019).","journal-title":"Clin. Exp. Dermatol."},{"key":"992_CR153","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1084\/jem.20061531","volume":"204","author":"S Nadkarni","year":"2007","unstructured":"Nadkarni, S., Mauri, C. & Ehrenstein, M. R. Anti-TNF-\u03b1 therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-\u03b2. J. Exp. Med. 204, 33\u201339 (2007).","journal-title":"J. Exp. Med."},{"key":"992_CR154","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1002269","volume":"13","author":"CC Li","year":"2015","unstructured":"Li, C. C., Munitic, I., Mittelstadt, P. R., Castro, E. & Ashwell, J. D. Suppression of dendritic cell-derived IL-12 by endogenous glucocorticoids is protective in LPS-induced sepsis. PLoS Biol. 13, e1002269 (2015).","journal-title":"PLoS Biol."},{"key":"992_CR155","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.4049\/jimmunol.170.9.4833","volume":"170","author":"X Hu","year":"2003","unstructured":"Hu, X., Li, W. P., Meng, C. & Ivashkiv, L. B. Inhibition of IFN-\u03b3 signaling by glucocorticoids. J. Immunol. 170, 4833\u20134839 (2003).","journal-title":"J. Immunol."},{"key":"992_CR156","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1096\/fj.06-7452com","volume":"21","author":"AC Liberman","year":"2007","unstructured":"Liberman, A. C. et al. The activated glucocorticoid receptor inhibits the transcription factor T\u2010bet by direct protein\u2010protein interaction. FASEB J. 21, 1177\u20131188 (2007).","journal-title":"FASEB J."},{"key":"992_CR157","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10875-012-9780-2","volume":"33","author":"UC Linhares","year":"2013","unstructured":"Linhares, U. C. et al. The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients. J. Clin. Immunol. 33, 179\u2013189 (2013).","journal-title":"J. Clin. Immunol."},{"key":"992_CR158","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1096\/fj.01-0245com","volume":"16","author":"J Galon","year":"2002","unstructured":"Galon, J. et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J. 16, 61\u201371 (2002).","journal-title":"FASEB J."},{"key":"992_CR159","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s10495-020-01629-x","volume":"25","author":"L Prenek","year":"2020","unstructured":"Prenek, L. et al. Regulatory T cells are less sensitive to glucocorticoid hormone induced apoptosis than CD4+ T cells. Apoptosis 25, 715\u2013729 (2020).","journal-title":"Apoptosis"},{"key":"992_CR160","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/art.41937","volume":"74","author":"PM Izmirly","year":"2022","unstructured":"Izmirly, P. M. et al. Evaluation of immune response and disease status in SLE patients following SARS\u2010CoV\u20102 vaccination. Arthritis Rheumatol. 74, 284\u2013294 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"992_CR161","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001898","volume":"8","author":"C Sieiro Santos","year":"2022","unstructured":"Sieiro Santos, C. et al. Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases. RMD Open 8, e001898 (2022).","journal-title":"RMD Open"},{"key":"992_CR162","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/eji.201948190","volume":"50","author":"GA Povoleri","year":"2020","unstructured":"Povoleri, G. A. et al. Anti\u2010TNF treatment negatively regulates human CD4+ T\u2010cell activation and maturation in vitro, but does not confer an anergic or suppressive phenotype. Eur. J. Immunol. 50, 445\u2013458 (2020).","journal-title":"Eur. J. Immunol."},{"key":"992_CR163","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.4049\/jimmunol.164.4.1768","volume":"164","author":"D Franchimont","year":"2000","unstructured":"Franchimont, D. et al. Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. J. Immunol. 164, 1768\u20131774 (2000).","journal-title":"J. Immunol."},{"key":"992_CR164","first-page":"1313","volume":"40","author":"M Bejad","year":"2022","unstructured":"Bejad, M., Bonilha, C. S., McInnes, I. B., Garside, P. & Benson, R. A. Tofacitinib inhibits CD4 T cell polarisation to Th1 during priming thereby leading to clinical impact in a model of experimental arthritis. Clin. Exp. Rheumatol. 40, 1313\u20131323 (2022).","journal-title":"Clin. Exp. Rheumatol."},{"key":"992_CR165","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1093\/rheumatology\/keab454","volume":"61","author":"J Aldridge","year":"2022","unstructured":"Aldridge, J. et al. Blood PD-1+ TFh and CTLA-4+CD4+ T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis. Rheumatology 61, 1233\u20131242 (2022).","journal-title":"Rheumatology"},{"key":"992_CR166","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1002\/art.40165","volume":"69","author":"GM Verstappen","year":"2017","unstructured":"Verstappen, G. M. et al. Attenuation of follicular helper T cell\u2013dependent B cell hyperactivity by abatacept treatment in primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol. 69, 1850\u20131861 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"992_CR167","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.immuni.2014.12.006","volume":"41","author":"JB Wing","year":"2014","unstructured":"Wing, J. B., Ise, W., Kurosaki, T. & Sakaguchi, S. Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. Immunity 41, 1013\u20131025 (2014).","journal-title":"Immunity"},{"key":"992_CR168","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fimmu.2012.00051","volume":"3","author":"A Schmidt","year":"2012","unstructured":"Schmidt, A., Oberle, N. & Krammer, P. H. Molecular mechanisms of Treg-mediated T cell suppression. Front. Immunol. 3, 51 (2012).","journal-title":"Front. Immunol."},{"key":"992_CR169","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/imr.12888","volume":"296","author":"JB Wing","year":"2020","unstructured":"Wing, J. B., Lim, E. L. & Sakaguchi, S. Control of foreign Ag\u2010specific Ab responses by Treg and Tfr. Immunol. Rev. 296, 104\u2013119 (2020).","journal-title":"Immunol. Rev."},{"key":"992_CR170","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar3542","volume":"13","author":"JJ Kobie","year":"2011","unstructured":"Kobie, J. J. et al. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res. Ther. 13, 1\u201312 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"992_CR171","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1006\/cimm.1998.1308","volume":"187","author":"F Bischof","year":"1998","unstructured":"Bischof, F. & Melms, A. Glucocorticoids inhibit CD40 ligand expression of peripheral CD4+ lymphocytes. Cell. Immunol. 187, 38\u201344 (1998).","journal-title":"Cell. Immunol."},{"key":"992_CR172","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.4049\/jimmunol.152.5.2163","volume":"152","author":"S Lederman","year":"1994","unstructured":"Lederman, S. et al. T-BAM\/CD40-L on helper T lymphocytes augments lymphokine-induced B cell Ig isotype switch recombination and rescues B cells from programmed cell death. J. Immunol. 152, 2163\u20132171 (1994).","journal-title":"J. Immunol."},{"key":"992_CR173","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaut.2016.10.005","volume":"77","author":"M Rizzi","year":"2017","unstructured":"Rizzi, M. et al. Impact of tofacitinib treatment on human B-cells in vitro and in vivo. J. Autoimmun. 77, 55\u201366 (2017).","journal-title":"J. Autoimmun."},{"key":"992_CR174","first-page":"S159","volume":"37","author":"M Lanzillotta","year":"2019","unstructured":"Lanzillotta, M. et al. Effects of glucocorticoids on B-cell subpopulations in patients with IgG4-related disease. Clin. Exp. Rheumatol. 37, S159\u2013S166 (2019).","journal-title":"Clin. Exp. Rheumatol."},{"key":"992_CR175","doi-asserted-by":"publisher","first-page":"102684","DOI":"10.1016\/j.jaut.2021.102684","volume":"123","author":"JC Graver","year":"2021","unstructured":"Graver, J. C. et al. Association of the CXCL9-CXCR3 and CXCL13-CXCR5 axes with B-cell trafficking in giant cell arteritis and polymyalgia rheumatica. J. Autoimmun. 123, 102684 (2021).","journal-title":"J. Autoimmun."},{"key":"992_CR176","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1084\/jem.20180595","volume":"216","author":"LM Franco","year":"2019","unstructured":"Franco, L. M. et al. Immune regulation by glucocorticoids can be linked to cell type-dependent transcriptional responses. J. Exp. Med. 216, 384\u2013406 (2019).","journal-title":"J. Exp. Med."},{"key":"992_CR177","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1002\/art.38736","volume":"66","author":"S Glaesener","year":"2014","unstructured":"Glaesener, S. et al. Distinct effects of methotrexate and etanercept on the B cell compartment in patients with juvenile idiopathic arthritis. Arthritis Rheumatol. 66, 2590\u20132600 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"992_CR178","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3109\/08916934.2013.798652","volume":"46","author":"J Thiel","year":"2013","unstructured":"Thiel, J. et al. B cell homeostasis is disturbed by immunosuppressive therapies in patients with ANCA-associated vasculitides. Autoimmunity 46, 429\u2013438 (2013).","journal-title":"Autoimmunity"},{"key":"992_CR179","doi-asserted-by":"publisher","first-page":"688","DOI":"10.4049\/jimmunol.180.2.688","volume":"180","author":"JH Anolik","year":"2008","unstructured":"Anolik, J. H. et al. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J. Immunol. 180, 688\u2013692 (2008).","journal-title":"J. Immunol."},{"key":"992_CR180","first-page":"317","volume":"35","author":"EA Haacke","year":"2017","unstructured":"Haacke, E. A. et al. Abatacept treatment of patients with primary Sj\u00f6gren\u2019s syndrome results in a decrease of germinal centres in salivary gland tissue. Clin. Exp. Rheumatol. 35, 317\u2013320 (2017).","journal-title":"Clin. Exp. Rheumatol."},{"key":"992_CR181","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DS Lee","year":"2021","unstructured":"Lee, D. S., Rojas, O. L. & Gommerman, J. L. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat. Rev. Drug Discov. 20, 179\u2013199 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"992_CR182","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.rdc.2015.08.002","volume":"42","author":"S Ramamoorthy","year":"2016","unstructured":"Ramamoorthy, S. & Cidlowski, J. A. Corticosteroids: mechanisms of action in health and disease. Rheum. Dis. Clin. 42, 15\u201331 (2016).","journal-title":"Rheum. Dis. Clin."},{"key":"992_CR183","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.4161\/cc.21018","volume":"11","author":"RA Samarasinghe","year":"2012","unstructured":"Samarasinghe, R. A., Witchell, S. F. & DeFranco, D. B. Cooperativity and complementarity: synergies in non-classical and classical glucocorticoid signaling. Cell Cycle 11, 2819\u20132827 (2012).","journal-title":"Cell Cycle"},{"key":"992_CR184","doi-asserted-by":"publisher","first-page":"E1322","DOI":"10.1152\/ajpendo.00678.2013","volume":"306","author":"L Besedovsky","year":"2014","unstructured":"Besedovsky, L. et al. Cortisol increases CXCR4 expression but does not affect CD62L and CCR7 levels on specific T cell subsets in humans. Am. J. Physiol. Endocrinol. Metab. 306, E1322\u2013E1329 (2014).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"992_CR185","doi-asserted-by":"publisher","first-page":"ra44","DOI":"10.1126\/scisignal.2001450","volume":"4","author":"Y He","year":"2011","unstructured":"He, Y. et al. Identification of a lysosomal pathway that modulates glucocorticoid signaling and the inflammatory response. Sci. Signal. 4, ra44\u2013ra44 (2011).","journal-title":"Sci. Signal."},{"key":"992_CR186","doi-asserted-by":"publisher","first-page":"709404","DOI":"10.3389\/fmed.2021.709404","volume":"8","author":"AD Wagner","year":"2021","unstructured":"Wagner, A. D. et al. Glucocorticoid effects on tissue residing immune cells in giant cell arteritis: importance of GM-CSF. Front. Med. 8, 709404 (2021).","journal-title":"Front. Med."},{"key":"992_CR187","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/cea.13061","volume":"48","author":"ES Chambers","year":"2018","unstructured":"Chambers, E. S. et al. Dendritic cell phenotype in severe asthma reflects clinical responsiveness to glucocorticoids. Clin. Exp. Allergy 48, 13\u201322 (2018).","journal-title":"Clin. Exp. Allergy"},{"key":"992_CR188","first-page":"1790","volume":"126","author":"S Bruscoli","year":"2015","unstructured":"Bruscoli, S. et al. Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B-cell survival and results in B-cell lymphocytosis in mice. Blood. J. Am. Soc. Hematol. 126, 1790\u20131801 (2015).","journal-title":"J. Am. Soc. Hematol."},{"key":"992_CR189","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMra050541","volume":"353","author":"T Rhen","year":"2005","unstructured":"Rhen, T. & Cidlowski, J. A. Antiinflammatory action of glucocorticoids \u2014 new mechanisms for old drugs. N. Engl. J. Med. 353, 1711\u20131723 (2005).","journal-title":"N. Engl. J. Med."},{"key":"992_CR190","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1172\/JCI109017","volume":"61","author":"A Saxon","year":"1978","unstructured":"Saxon, A., Stevens, R. H., Ramer, S. J., Clements, P. J. & Yu, D. T. Glucocorticoids administered in vivo inhibit human suppressor T lymphocyte function and diminish B lymphocyte responsiveness in in vitro immunoglobulin synthesis. J. Clin. Invest. 61, 922\u2013930 (1978).","journal-title":"J. Clin. Invest."},{"key":"992_CR191","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1002\/art.38805","volume":"66","author":"CF Spurlock III","year":"2014","unstructured":"Spurlock, C. F. III, Tossberg, J. T., Matlock, B. K., Olsen, N. J. & Aune, T. M. Methotrexate inhibits NF\u2010\u03baB activity via long intergenic (noncoding) RNA\u2013p21 induction. Arthritis Rheumatol. 66, 2947\u20132957 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"992_CR192","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1445-5994.2008.01737.x","volume":"39","author":"S Lester","year":"2009","unstructured":"Lester, S. et al. Treatment\u2010induced stable, moderate reduction in blood cell counts correlate to disease control in early rheumatoid arthritis. Intern. Med. J. 39, 296\u2013303 (2009).","journal-title":"Intern. Med. J."},{"key":"992_CR193","doi-asserted-by":"publisher","first-page":"7561661","DOI":"10.1155\/2022\/7561661","volume":"2022","author":"E Elm\u00e9r","year":"2022","unstructured":"Elm\u00e9r, E. et al. Methotrexate treatment suppresses monocytes in nonresponders to pneumococcal conjugate vaccine in rheumatoid arthritis patients. J. Immunol. Res. 2022, 7561661 (2022).","journal-title":"J. Immunol. Res."},{"key":"992_CR194","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1006\/clim.1998.4671","volume":"91","author":"S Hirohata","year":"1999","unstructured":"Hirohata, S., Yanagida, T., Hashimoto, H., Tomita, T. & Ochi, T. Suppressive influences of methotrexate on the generation of CD14+ monocyte-lineage cells from bone marrow of patients with rheumatoid arthritis. Clin. Immunol. 91, 84\u201389 (1999).","journal-title":"Clin. Immunol."},{"key":"992_CR195","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1136\/annrheumdis-2015-208736","volume":"75","author":"C Municio","year":"2016","unstructured":"Municio, C. et al. Methotrexate selectively targets human proinflammatory macrophages through a thymidylate synthase\/p53 axis. Ann. Rheum. Dis. 75, 2157\u20132165 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR196","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1046\/j.1365-2249.1999.01022.x","volume":"118","author":"K Hildner","year":"1999","unstructured":"Hildner, K. et al. Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis. Clin. Exp. Immunol. 118, 137\u2013146 (1999).","journal-title":"Clin. Exp. Immunol."},{"key":"992_CR197","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/rheumatology\/keg323","volume":"42","author":"AH Gerards","year":"2003","unstructured":"Gerards, A. H., De Lathouder, S., De Groot, E., Dijkmans, B. & Aarden, L. Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology 42, 1189\u20131196 (2003).","journal-title":"Rheumatology"},{"key":"992_CR198","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.pharep.2014.05.004","volume":"66","author":"G Cessak","year":"2014","unstructured":"Cessak, G. et al. TNF inhibitors \u2014 mechanisms of action, approved and off-label indications. Pharmacol. Rep. 66, 836\u2013844 (2014).","journal-title":"Pharmacol. Rep."},{"key":"992_CR199","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.5114\/aoms.2014.47827","volume":"10","author":"K Lis","year":"2014","unstructured":"Lis, K., Kuzawi\u0144ska, O. & Ba\u0142kowiec-Iskra, E. Tumor necrosis factor inhibitors \u2014 state of knowledge. Arch. Med. Sci. 10, 1175\u20131185 (2014).","journal-title":"Arch. Med. Sci."},{"key":"992_CR200","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","volume":"24","author":"J Baddley","year":"2018","unstructured":"Baddley, J. et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-\u03b1 agents). Clin. Microbiol. Infect. 24, S10\u2013S20 (2018).","journal-title":"Clin. Microbiol. Infect."},{"key":"992_CR201","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1084\/jem.184.4.1397","volume":"184","author":"M Pasparakis","year":"1996","unstructured":"Pasparakis, M., Alexopoulou, L., Episkopou, V. & Kollias, G. Immune and inflammatory responses in TNF\u03b1-deficient mice: a critical requirement for TNF\u03b1 in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med. 184, 1397\u20131411 (1996).","journal-title":"J. Exp. Med."},{"key":"992_CR202","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1365-2133.2007.07945.x","volume":"157","author":"C Bedini","year":"2007","unstructured":"Bedini, C., Nasorri, F., Girolomoni, G., de Pit\u00e0, O. & Cavani, A. Antitumour necrosis factor\u2010\u03b1 chimeric antibody (infliximab) inhibits activation of skin\u2010homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function. Br. J. Dermatol. 157, 249\u2013258 (2007).","journal-title":"Br. J. Dermatol."},{"key":"992_CR203","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1084\/jem.20071094","volume":"204","author":"LC Zaba","year":"2007","unstructured":"Zaba, L. C. et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 204, 3183\u20133194 (2007).","journal-title":"J. Exp. Med."},{"key":"992_CR204","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1016\/j.vaccine.2019.05.037","volume":"37","author":"\u00c5 Laestadius","year":"2019","unstructured":"Laestadius, \u00c5. et al. Altered proportions of circulating CXCR5+ helper T cells do not dampen influenza vaccine responses in children with rheumatic disease. Vaccine 37, 3685\u20133693 (2019).","journal-title":"Vaccine"},{"key":"992_CR205","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka, Y., Luo, Y., O\u2019Shea, J. J. & Nakayamada, S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat. Rev. Rheumatol. 18, 133\u2013145 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"992_CR206","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","volume":"24","author":"M Reinwald","year":"2018","unstructured":"Reinwald, M. et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin. Microbiol. Infect. 24, S53\u2013S70 (2018).","journal-title":"Clin. Microbiol. Infect."},{"key":"992_CR207","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1136\/annrheumdis-2013-203756","volume":"73","author":"S Kubo","year":"2014","unstructured":"Kubo, S. et al. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann. Rheum. Dis. 73, 2192\u20132198 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR208","doi-asserted-by":"publisher","first-page":"102684","DOI":"10.1016\/j.ebiom.2020.102684","volume":"53","author":"A Schmidt","year":"2020","unstructured":"Schmidt, A. et al. Complex human adenoid tissue-based ex vivo culture systems reveal anti-inflammatory drug effects on germinal center T and B cells. EBioMedicine 53, 102684 (2020).","journal-title":"EBioMedicine"},{"key":"992_CR209","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/BOR.0000000000000491","volume":"30","author":"M Bonelli","year":"2018","unstructured":"Bonelli, M. & Scheinecker, C. How does abatacept really work in rheumatoid arthritis? Curr. Opin. Rheumatol. 30, 295\u2013300 (2018).","journal-title":"Curr. Opin. Rheumatol."},{"key":"992_CR210","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/art.38982","volume":"67","author":"F Moret","year":"2015","unstructured":"Moret, F., Bijlsma, J., Lafeber, F. & Van Roon, J. The efficacy of abatacept in reducing synovial T cell activation by CD1c myeloid dendritic cells is overruled by the stimulatory effects of T cell\u2013activating cytokines. Arthritis Rheumatol. 67, 637\u2013644 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"992_CR211","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-018-1527-x","volume":"20","author":"A Bozec","year":"2018","unstructured":"Bozec, A. et al. Abatacept blocks anti-citrullinated protein antibody and rheumatoid factor mediated cytokine production in human macrophages in IDO-dependent manner. Arthritis Res. Ther. 20, 1\u20139 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"992_CR212","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/rheumatology\/kex012","volume":"57","author":"S Nakayamada","year":"2018","unstructured":"Nakayamada, S. et al. Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis. Rheumatology 57, 164\u2013174 (2018).","journal-title":"Rheumatology"},{"key":"992_CR213","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41584-020-0374-8","volume":"16","author":"JC Broen","year":"2020","unstructured":"Broen, J. C. & van Laar, J. M. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. Nat. Rev. Rheumatol. 16, 167\u2013178 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"992_CR214","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2147\/IJNRD.S335371","volume":"14","author":"ME Alamilla-Sanchez","year":"2021","unstructured":"Alamilla-Sanchez, M. E., Alcala-Salgado, M. A., Alonso-Bello, C. D. & Fonseca-Gonzalez, G. T. Mechanism of action and efficacy of immunosuppressors in lupus nephritis. Int. J. Nephrol. Renovasc. Dis. 14, 441\u2013458 (2021).","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"992_CR215","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar3835","volume":"14","author":"S Eickenberg","year":"2012","unstructured":"Eickenberg, S. et al. Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosus. Arthritis Res. Ther. 14, 1\u201314 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"992_CR216","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/eji.200324174","volume":"34","author":"NH Litjens","year":"2004","unstructured":"Litjens, N. H. et al. Monomethylfumarate affects polarization of monocyte\u2010derived dendritic cells resulting in down\u2010regulated Th1 lymphocyte responses. Eur. J. Immunol. 34, 565\u2013575 (2004).","journal-title":"Eur. J. Immunol."},{"key":"992_CR217","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","volume":"24","author":"KL Winthrop","year":"2018","unstructured":"Winthrop, K. L. et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin. Microbiol. Infect. 24, S21\u2013S40 (2018).","journal-title":"Clin. Microbiol. Infect."},{"key":"992_CR218","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1136\/annrheumdis-2012-201310","volume":"72","author":"Y Shirota","year":"2013","unstructured":"Shirota, Y. et al. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 72, 118\u2013128 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR219","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier, E. & D\u00f6rner, T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat. Rev. Rheumatol. 16, 155\u2013166 (2020).","journal-title":"Nat. Rev. Rheumatol."},{"key":"992_CR220","first-page":"440","volume":"42","author":"R Matasi\u00e6","year":"2001","unstructured":"Matasi\u00e6, R., Dietz, A. B. & Vuk-Pavlovi\u00e6, S. Maturation of human dendritic cells as sulfasalazine target. Croat. Med. J. 42, 440\u2013445 (2001).","journal-title":"Croat. Med. J."},{"key":"992_CR221","doi-asserted-by":"publisher","first-page":"110848","DOI":"10.1016\/j.biopha.2020.110848","volume":"132","author":"J Han","year":"2020","unstructured":"Han, J. et al. The mechanisms of hydroxychloroquine in rheumatoid arthritis treatment: Inhibition of dendritic cell functions via Toll like receptor 9 signaling. Biomed. Pharmacother. 132, 110848 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"992_CR222","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.vaccine.2005.08.105","volume":"24","author":"K Goodwin","year":"2006","unstructured":"Goodwin, K., Viboud, C. & Simonsen, L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24, 1159\u20131169 (2006).","journal-title":"Vaccine"},{"key":"992_CR223","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.4049\/jimmunol.172.6.3437","volume":"172","author":"Y Deng","year":"2004","unstructured":"Deng, Y., Jing, Y., Campbell, A. E. & Gravenstein, S. Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J. Immunol. 172, 3437\u20133446 (2004).","journal-title":"J. Immunol."},{"key":"992_CR224","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1210\/jcem-72-1-39","volume":"72","author":"NV Esteban","year":"1991","unstructured":"Esteban, N. V. et al. Daily cortisol production rate in man determined by stable isotope dilution\/mass spectrometry. J. Clin. Endocrinol. Metab. 72, 39\u201345 (1991).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"992_CR225","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1016\/S2665-9913(22)00102-3","volume":"4","author":"L Boekel","year":"2022","unstructured":"Boekel, L. et al. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. Lancet Rheumatol. 4, e417\u2013e429 (2022).","journal-title":"Lancet Rheumatol."},{"key":"992_CR226","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002187","volume":"8","author":"J Liew","year":"2022","unstructured":"Liew, J. et al. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open 8, e002187 (2022).","journal-title":"RMD Open"},{"key":"992_CR227","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1136\/annrheumdis-2021-222045","volume":"81","author":"C Shen","year":"2022","unstructured":"Shen, C. et al. Efficacy of COVID-19 vaccines in patients taking immunosuppressants. Ann. Rheum. Dis. 81, 875\u2013880 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"992_CR228","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"992_CR229","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1172\/JCI57834","volume":"121","author":"S Sasaki","year":"2011","unstructured":"Sasaki, S. et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J. Clin. Invest. 121, 3109\u20133119 (2011).","journal-title":"J. Clin. Invest."},{"key":"992_CR230","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1128\/CVI.00386-12","volume":"19","author":"A Chioato","year":"2012","unstructured":"Chioato, A. et al. Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study. Clin. Vaccin. Immunol. 19, 1597\u20131602 (2012).","journal-title":"Clin. Vaccin. Immunol."},{"key":"992_CR231","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001018","volume":"5","author":"P Richi","year":"2019","unstructured":"Richi, P. et al. Secukinumab does not impair the immunogenic response to the influenza vaccine in patients. RMD Open 5, e001018 (2019).","journal-title":"RMD Open"},{"key":"992_CR232","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/vaccines8030455","volume":"8","author":"L Doornekamp","year":"2020","unstructured":"Doornekamp, L. et al. High immunogenicity to influenza vaccination in Crohn\u2019s disease patients treated with ustekinumab. Vaccines 8, 3 (2020).","journal-title":"Vaccines"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-00992-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-00992-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-00992-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T13:11:18Z","timestamp":1692709878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-00992-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":232,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["992"],"URL":"https:\/\/doi.org\/10.1038\/s41584-023-00992-8","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]},"assertion":[{"value":"8 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}